Get 40% Off
💰 Warren Buffett reveals a $6.72 billion stake in ChubbCopy Portfolios

Magellan Health (MGLN) Q2 Earnings Beat Estimates, Down YoY

Published 07/30/2019, 09:00 PM
Updated 07/09/2023, 06:31 AM
AAPL
-
ELV
-
UNH
-
MGLN
-
WCG
-

Magellan Health, Inc.’s (NASDAQ:MGLN) earnings per share of 86 cents beat the Zacks Consensus Estimate by 3.6%, but were down 5.5% year over year.

Revenues of $1.81 billion were down 1.1% year over year, due to reduction in Magellan Complete Care (MCC) Florida business and Medicare Part D footprint and PBM healthplan contract loss. This was partly offset by growth in MCC of Virginia and new PBM employer business. Revenues beat the Zacks Consensus Estimate by 4%.

Magellan Health, Inc. Price, Consensus and EPS Surprise

Segment profit of $45.6 million was down 18% year over year due to decline in contribution from its Healthcare segment, partly offset by a slight increase in profit from Pharmacy Benefit Management (PBM) segment.

Total cost and expense of $1.79 increased 1.1% year over year due to higher cost of goods sold.

Capital Position

Cash flow from operations for the six months ended Jun 30, 2019 was $21.1 million, down 28% year over year.

As of Jun 30, 2019, the company's cash and cash equivalents totaled $272.3 million, up 4% from year-end 2018 level.

Guidance

For 2019, the company affirmed its previously issued earnings per share guidance range of $3.70-$4.69 and revenues of $7-$7.2 billion.

Our Take

Earnings visibility provided by the management in the reported quarter provides us some relief on the company’s ability to deliver better results in the second half. Moreover, the quarter’s earnings beat and reiteration of 2019 guidance reflect improving business fundamentals, particularly after the earnings miss and guidance cut in the recent past. A rebound in the company’s PBM business led by reduction in cost of goods sold and strong medical pharmacy business is particularly impressive.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Zacks Rank and Performance of Other Players

Magellan Health carries a Zacks Rank #3 (Hold). Other players in the medical space that have reported second-quarter earnings so far are UnitedHealth Group, Inc. (NYSE:UNH) , Anthem Inc. (NYSE:ANTM) and Wellcare Health Plans, Inc. (NYSE:WCG) , each beating their Zacks Consensus Estimate by 4.1%, 0.65% and 5.12%, respectively.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>



Magellan Health, Inc. (MGLN): Free Stock Analysis Report

UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report

Anthem, Inc. (ANTM): Free Stock Analysis Report

WellCare Health Plans, Inc. (WCG): Free Stock Analysis Report

Original post

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.